Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Witty On Pricing: Oncology 'No Safe Haven'

This article was originally published in Scrip

Executive Summary

"It's time for industry and payers to start thinking about different pricing models, and it's going to require some transparency about what everything costs," said Sir Andrew Witty, speaking to Scrip on 18 April. "Lots of people will say pricing is not an issue in oncology. It's going to be an issue – it's inevitable."

You may also be interested in...



"Crazy" European Orphan Drug Pricing System Has To End

Eurordis head Yann Le Cam outlines his vision for the future of orphan drug pricing in Europe.

Orphan Drug Pricing: More Dialogue And Collaboration Needed, Says EURORDIS

Pharmaceutical companies, payers and other stakeholders need to work more collaboratively if the problems surrounding the pricing and reimbursement of orphan medicines are to be tackled successfully in Europe, says the rare disease organization EURORDIS.

What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK

The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.

Topics

UsernamePublicRestriction

Register

LL1134446

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel